We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.
- Authors
Shang, Yuru; Zhang, Xianbin; Lu, Lili; Jiang, Ke; Krohn, Mathias; Matschos, Stephanie; Mullins, Christina Susanne; Vollmar, Brigitte; Zechner, Dietmar; Gong, Peng; Linnebacher, Michael
- Abstract
<bold>Background: </bold>Recent evidence proves that intravenous human immunoglobulin G (IgG) can impair cancer cell viability. However, no study evaluated whether IgG application benefits cancer patients receiving chemotherapeutics.<bold>Methods: </bold>Influence of pharmaceutical-grade human IgG on the viability of a series of patient-derived colon cancer cell lines with and without chemotherapeutic intervention was determined. Cell death was analysed flow cytometrically. In addition, the influence of oxaliplatin and IgG on the ERK1/2-signalling pathway was evaluated by western blots.<bold>Results: </bold>We evaluated the effects of pharmaceutical IgG, such as PRIVIGEN® IgG and Tonglu® IgG, in combination with chemotherapeutics. We did not observe any significant effects of IgG on tumour cell viability directly; however, human IgG significantly impaired the anti-tumoral effects of oxaliplatin. Primary cancer cell lines express IgG receptors and accumulate human IgG intracellularly. Moreover, while oxaliplatin induced the activation of ERK1/2, the pharmaceutical IgG inhibited ERK1/2 activity.<bold>Conclusions: </bold>The present study demonstrates that pharmaceutical IgG, such as PRIVIGEN® IgG and Tonglu® IgG, can impair the anti-carcinoma activity of oxaliplatin. These data strongly suggest that therapeutic IgG as co-medication might have harmful side effects in cancer patients. The clinical significance of these preclinical observations absolutely advises further preclinical, as well as epidemiological and clinical research.
- Publication
British Journal of Cancer, 2021, Vol 124, Issue 8, p1411
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/s41416-021-01272-6